Associated Regional and University Pathologists INC

Associated Regional and University Pathologists INC was paid $8.13M by Medicaid between Jan 2018 and Dec 2024, across 268 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 11% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Utah

Rank by total paid#7 of 35

Median peer was paid$385K

This provider vs. median21×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	20,702	$467K
2019	59,194	$1.16M
2020	60,956	$1.20M
2021	76,394	$1.49M
2022	60,576	$1.37M
2023	56,344	$1.34M
2024incomplete	42,839	$1.10M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	11%	13,372	10,820	$864K
83655		5.7%	34,165	32,889	$463K
87902		4.8%	1,792	1,662	$391K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.9%	12,197	9,920	$318K
84403		2.6%	9,603	9,298	$212K
86235		2.4%	3,784	3,195	$198K
84402		2.2%	8,637	8,318	$178K
86003		2.0%	2,760	2,450	$165K
86480		2.0%	3,338	3,255	$162K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.9%	2,596	2,448	$158K
86317		1.8%	3,932	2,515	$148K
83516		1.8%	9,059	7,806	$143K

256 more codes

84445		1.7%	3,117	$136K
87480		1.6%	12,138	$131K
87660		1.6%	12,138	$130K
87510		1.6%	12,139	$130K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	1.5%	1,590	$123K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.5%	1,316	$123K
87522	Neg quan hep c or qual rna	1.4%	2,774	$114K
84425		1.3%	6,285	$109K
83013		1.3%	3,566	$107K
83520		1.3%	6,831	$105K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.3%	2,790	$104K
82652		1.2%	2,984	$97K
86341		1.2%	3,862	$94K
82024		1.2%	3,143	$94K
84207		1.1%	3,790	$88K
82088		<1%	2,071	$70K
83993		<1%	3,563	$67K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,602	$66K
81511		<1%	3,377	$62K
83921		<1%	3,894	$61K
83498		<1%	2,911	$61K
86039		<1%	4,632	$53K
86256		<1%	4,317	$51K
87799		<1%	995	$51K
86376		<1%	3,646	$51K
86038		<1%	3,370	$49K
86694		<1%	3,901	$48K
84244		<1%	2,398	$48K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	218	$47K
86146		<1%	1,102	$45K
82627		<1%	1,982	$43K
84305		<1%	2,318	$42K
82525		<1%	3,790	$42K
81206		<1%	691	$42K
87517		<1%	1,113	$41K
84630		<1%	4,136	$40K
84270		<1%	2,164	$40K
84446		<1%	2,745	$39K
86200		<1%	3,097	$39K
86800		<1%	2,591	$39K
82239		<1%	2,548	$37K
82103		<1%	2,662	$36K
87209		<1%	1,911	$36K
82784		<1%	2,607	$34K
86812		<1%	1,511	$33K
81240		<1%	603	$32K
86147		<1%	723	$32K
86225		<1%	2,116	$32K
83835		<1%	2,119	$32K
82104		<1%	2,019	$30K
86787		<1%	2,343	$29K
84590		<1%	2,634	$29K
82105		<1%	1,673	$28K
86682		<1%	2,049	$28K
80349		<1%	1,824	$27K
82085		<1%	2,703	$27K
86708		<1%	2,280	$27K
82164		<1%	2,252	$26K
80175		<1%	2,258	$26K
80177		<1%	2,095	$26K
86780		<1%	2,163	$25K
86255		<1%	1,966	$24K
86381		<1%	1,191	$24K
86665		<1%	779	$24K
84080		<1%	1,803	$23K
82365		<1%	1,823	$22K
84432		<1%	1,454	$22K
87338		<1%	2,176	$22K
82172		<1%	759	$22K
80348		<1%	1,644	$21K
87449		<1%	1,833	$21K
80321		<1%	1,894	$20K
86316		<1%	1,080	$20K
83880		<1%	600	$19K
86162		<1%	902	$19K
82670		<1%	654	$18K
87177		<1%	1,947	$17K
80323		<1%	946	$17K
80361		<1%	1,053	$17K
84182		<1%	171	$16K
87536		<1%	238	$16K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,833	$16K
80365		<1%	1,052	$16K
82668		<1%	1,002	$16K
83916		<1%	613	$16K
80183		<1%	1,218	$16K
80235		<1%	708	$15K
82610		<1%	987	$15K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	559	$14K
87563		<1%	431	$14K
84165		<1%	1,358	$14K
87631		<1%	137	$13K
86592		<1%	3,215	$13K
82785		<1%	804	$13K
82379		<1%	663	$12K
82390		<1%	1,062	$12K
86015		<1%	1,289	$12K
80359		<1%	808	$12K
82657		<1%	692	$11K
84480		<1%	929	$11K
80325		<1%	757	$11K
86618		<1%	650	$11K
86364		<1%	1,173	$10K
87350		<1%	868	$9K
86334		<1%	494	$9K
86762		<1%	649	$9K
87899		<1%	1,209	$9K
87468		<1%	333	$9K
84436		<1%	1,314	$9K
80159		<1%	653	$9K
86337		<1%	385	$8K
87484		<1%	295	$8K
86611		<1%	361	$8K
83695		<1%	711	$8K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	272	$8K
82787		<1%	539	$8K
87529		<1%	150	$7K
87469		<1%	280	$7K
80197		<1%	749	$7K
86707		<1%	640	$7K
83519		<1%	432	$7K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	241	$7K
81229		<1%	15	$7K
81207		<1%	99	$6K
80201		<1%	545	$6K
86036		<1%	702	$6K
82157		<1%	220	$6K
87385		<1%	505	$6K
86778		<1%	447	$6K
82653		<1%	359	$6K
85613		<1%	712	$6K
85246		<1%	362	$6K
87305		<1%	546	$6K
84702		<1%	409	$6K
86300		<1%	462	$5K
86664		<1%	339	$5K
82166		<1%	193	$5K
86747		<1%	194	$5K
87341		<1%	514	$5K
86617		<1%	216	$5K
82671		<1%	252	$5K
82397		<1%	386	$5K
84481		<1%	352	$5K
87593		<1%	81	$5K
86360		<1%	122	$5K
86663		<1%	349	$5K
81270		<1%	87	$5K
82042		<1%	712	$5K
85245		<1%	289	$5K
82747		<1%	262	$5K
86757		<1%	115	$5K
82180		<1%	544	$4K
82384		<1%	192	$4K
84155		<1%	1,235	$4K
86698		<1%	184	$4K
82175		<1%	234	$4K
88142		<1%	201	$4K
86160		<1%	270	$4K
85730		<1%	647	$4K
83883		<1%	333	$4K
80203		<1%	306	$4K
86788		<1%	231	$4K
86359		<1%	121	$4K
86593		<1%	826	$4K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	119	$3K
83021		<1%	327	$3K
85240		<1%	289	$3K
86789		<1%	221	$3K
84146		<1%	187	$3K
82040		<1%	622	$3K
80346		<1%	202	$3K
80339		<1%	130	$3K
83825		<1%	186	$3K
81241		<1%	209	$3K
86361		<1%	117	$3K
86696		<1%	200	$3K
85610		<1%	665	$3K
84460		<1%	501	$2K
82595		<1%	416	$2K
84450		<1%	499	$2K
87252		<1%	158	$2K
84255		<1%	102	$2K
84075		<1%	548	$2K
80164		<1%	206	$2K
88184		<1%	60	$2K
82626		<1%	114	$2K
82955		<1%	246	$2K
82523		<1%	128	$2K
80165		<1%	192	$2K
82977		<1%	261	$2K
86258		<1%	152	$2K
86644		<1%	134	$2K
82705		<1%	387	$2K
84482		<1%	149	$2K
81208		<1%	14	$2K
82985		<1%	123	$2K
84704		<1%	115	$2K
82530		<1%	110	$2K
80299		<1%	113	$2K
86356		<1%	12	$2K
86769		<1%	32	$1K
86695		<1%	136	$1K
85306		<1%	71	$1K
86606		<1%	78	$1K
88185		<1%	13	$1K
81256		<1%	129	$1K
86777		<1%	93	$1K
83090		<1%	69	$1K
84520		<1%	261	$1K
82533		<1%	73	$1K
83525		<1%	173	$996.66
86645		<1%	92	$976.26
82300		<1%	41	$929.03
81508		<1%	15	$920.25
86231		<1%	91	$783.17
87253		<1%	74	$780.76
84238		<1%	19	$765.59
87255		<1%	27	$726.62
84597		<1%	66	$688.40
86041		<1%	48	$662.13
80230		<1%	17	$655.69
84160		<1%	100	$646.23
86042		<1%	45	$643.73
80345		<1%	70	$631.96
82017		<1%	27	$619.11
84252		<1%	29	$584.73
87535		<1%	13	$541.32
86765		<1%	32	$406.77
86709		<1%	51	$404.52
83001		<1%	28	$404.22
84681		<1%	45	$378.33
87015		<1%	46	$375.39
84260		<1%	14	$362.84
86340		<1%	25	$346.43
85305		<1%	38	$336.39
84153		<1%	32	$327.15
86706		<1%	31	$324.13
85302		<1%	32	$320.28
84154		<1%	27	$317.95
80180		<1%	25	$296.88
86803		<1%	32	$295.52
84433		<1%	64	$253.82
81291		<1%	38	$237.34
86704		<1%	25	$236.54
85247		<1%	12	$212.90
86612		<1%	12	$187.92
87116		<1%	17	$180.00
86666		<1%	14	$169.85
84439		<1%	31	$169.66
86705		<1%	17	$168.86
86336		<1%	12	$164.92
87206		<1%	30	$164.61
85303		<1%	12	$146.13
86635		<1%	13	$107.33
81599		<1%	91	$87.75
81479	Unlisted molecular pathology procedure	0%	30	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTHEURER, ANDREW (PRESIDENT)